Personalis at Neoantigen Summit Europe: April 21-22, 2021

Presentation

Maik Pruess

Maik Pruess, PhD
Senior Field Application Scientist
Personalis, Inc.

Wednesday, APR 21 | 4:15 PM CEST

Personalis® NeXT Platform® for High-Accuracy Neoantigen Prediction, Composite Biomarker Identification and Personalized Cancer Therapy Development

  • NEOPS™ (Neoantigen Presentation Score) combines the tumor genomic and immune-related analytics of the Personalis® NeXT Platform™ to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers.
  • SHERPA™ (Systematic HLA Epitope Ranking Pan Algorithm) improves neoantigen presentation prediction compared to other in silico methods, and can enable more predictive biomarkers for cancer therapy as well as facilitate the development of neoantigen-targeting, personalized cancer therapies.
  • NEOPS, SHERPA, and other recent enhancements to the company’s HLA typing, HLA LOH detection and transcriptome analytics represent the latest update to the comprehensive suite of advanced analytical engines of the Personalis NeXT Platform™. Utilizing an augmented exome and transcriptome-based approach, NeXT enables the simultaneous analysis of both a tumor and its immune microenvironment from a single tumor specimen to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response.